Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures

Archives of Public Health

Olivier Ethgen²  Mickaël Hiligsmann¹  Nansa Burlet²  Jean-Yves Reginster² 

[1] Department of Health Services Research, Maastricht University, Maastricht, The Netherlands

[2] Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium

关键词: Osteoporosis;    Fracture;    Vitamin D;    Dairy products;    Cost-effectiveness;    Osteoporosis;   

Others  :  1234991
DOI  :  10.1186/s13690-015-0099-3

 received in 2015-09-09, accepted in 2015-09-24,  发布年份 2015

【 摘 要 】

Background

Dietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of osteoporosis-related fractures but their public health and economic impact has never been studied.

Methods

We designed a population-based model to forecast the potential health outcomes and medical effectiveness of the daily administration of dairy supplements containing 800 IU of vitamin D and 1 g of calcium in cohorts of subjects, from both genders, aged 50, 60, 70 and 80 years. Annual costs of dairy products were tested at €150, €250 and €350.

Results

In total, the daily intake of vitamin-D rich dairy products reduces by 30,376 and 16,105 events the number of osteoporotic fractures in women and men respectively and permits to gain 6605 and 6144 life-years, in women and men respectively. This intervention is cost-effective from 70 years on in the general population and from 60 years on in patients at increased risk of osteoporotic fractures.

Conclusion

The recommendation to use dairy products as the preferred source of calcium and vitamin D in aging males and females is supported by public health and health economic analyses.

【 授权许可】

   
2015 Ethgen et al.

【 参考文献 】

• [1]Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D: Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997, 7(4):390-406.
• [2]Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al.: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013, 24(1):23-57.
• [3]Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, et al.: Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013, 8:137.
• [4]Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV, et al.: Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011, 6:59-155.
• [5]Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al.: Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013, 8:136.
• [6]Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd: Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993, 137(9):1001-5.
• [7]Rizzoli R, Boonen S, Brandi ML, Bruyere O, Cooper C, Kanis JA, et al.: Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 2013, 29(4):305-13.
• [8]Bruyere O, Slomian J, Beaudart C, Buckinx F, Cavalier E, Gillain S, et al.: Prevalence of vitamin D inadequacy in European women aged over 80 years. Arch Gerontol Geriatr 2014, 59(1):78-82.
• [9]Bruyere O, Malaise O, Neuprez A, Collette J, Reginster JY: Prevalence of vitamin D inadequacy in European postmenopausal women. Curr Med Res Opin 2007, 23(8):1939-44.
• [10]Bruyere O, De Cock C, Mottet C, Neuprez A, Malaise O, Reginster JY: Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutr 2009, 12(1):111-4.
• [11]Bruyere O, Cavalier E, Souberbielle JC, Bischoff-Ferrari HA, Beaudart C, Buckinx F, et al.: Effects of vitamin D in the elderly population: current status and perspectives. Arch Public Health 2014, 72(1):32. BioMed Central Full Text
• [12]Rizzoli R, Stevenson JC, Bauer JM, van Loon LJ, Walrand S, Kanis JA, et al.: The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas 2014, 79(1):122-32.
• [13]Hiligsmann M, Ben Sedrine W, Bruyere O, Evers SM, Rabenda V, Reginster JY: Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. Eur J Pub Health 2015, 25(1):20-5.
• [14]Reginster JY: Calcium and vitamin D for osteoporotic fracture risk. Lancet 2007, 370(9588):632-4.
• [15]Lotters FJ, Lenoir-Wijnkoop I, Fardellone P, Rizzoli R, Rocher E, Poley MJ: Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int 2013, 24(1):139-50.
• [16]Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY: Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009, 12(5):687-96.
• [17]Hiligsmann M, Vanoverberghe M, Neuprez A, Bruyere O, Reginster JY: Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2010, 10(4):359-66.
• [18]Hiligsmann M, Reginster JY: Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. PharmacoEconomics 2011, 29(10):895-911.
• [19]Ethgen O, Standaert B: Population- versus cohort-based modelling approaches. PharmacoEconomics 2012, 30(3):171-81.
• [20]SPF Economie - Direction Générale Statistique et Information Economique.. http://economie.fgov.be/fr/modules/publications/statistiques/economie/prix_a_la_consommation_a_partir_de_1920_et_indice_sante_a_partir_de_1994.jsp webcite
• [21]SPF Economie - Direction Générale Statistique et Information Economique.. http://statbel.fgov.be/fr/modules/publications/statistiques/population/downloads/population_au_1er_janvier_2014-2061.jsp webcite
• [22]Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al.: Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010, 152(6):380-90.
• [23]Hiligsmann M, Bruyere O, Roberfroid D, Dubois C, Parmentier Y, Carton J, et al.: Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000–2007). Arthritis Res 2012, 64(5):744-50.
• [24]Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al.: Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000, 11(8):669-74.
• [25]Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15(4):721-39.
• [26]Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al.: A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004, 35(2):375-82.
• [27]Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P: Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007, 92(4):1415-23.
• [28]Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A: Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370(9588):657-66.
• [29]Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al.: Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169(6):551-61.
• [30]Cleemput I, van Wilder P, Huybrechts M, Vrijens F: Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009, 12(4):441-9.
• [31]Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, et al.: Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 2000, 11(5):373-80.
• [32]Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA: Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003, 14(5):383-8.
• [33]Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al.: Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013, 369(18):1715-25.
• [34]Gomez JA, Lepetic A, Demarteau N: Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health 2014, 14:1222. BioMed Central Full Text
• [35]Johnell O, Kanis JA: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17(12):1726-33.
• [36]Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, et al.: A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. PharmacoEconomics 2015, 33(3):205-24.
• [37]Rodriguez Barrios JM, Perez Alcantara F, Crespo Palomo C, Gonzalez Garcia P, Anton De Las Heras E, Brosa Riestra M: The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ 2012, 13(6):723-40.
• [38]Azimi NA, Welch HG: The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 1998, 13(10):664-9.
• [39]Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146(4):473-81.
• [40]Owens DK: Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998, 13(10):716-7.
• [41]World Health Organization (WHO). Choosing interventions that are cost effective. Available at http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 25 Apr 2009.
• [42]Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, et al.: A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 2005, 16(7):799-804.
• [43]Michaelsson K, Wolk A, Langenskiold S, Basu S, Warensjo Lemming E, Melhus H, et al.: Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ 2014, 349:g6015.
• [44]van den Berg P, van Haard PM, van den Bergh JP, Niesten DD, van der Elst M, Schweitzer DH: First quantification of calcium intake from calcium-dense dairy products in Dutch fracture patients (the Delft cohort study). Nutrients 2014, 6(6):2404-18.
• [45]Wlodarek D, Glabska D, Kolota A, Adamczyk P, Czekajlo A, Grzeszczak W, et al.: Calcium intake and osteoporosis: the influence of calcium intake from dairy products on hip bone mineral density and fracture incidence - a population-based study in women over 55 years of age. Public Health Nutr 2014, 17(2):383-9.
• [46]Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, Kanis JA, Orav EJ, Staehelin HB, et al.: Milk intake and risk of hip fracture in men and women: a meta-analysis of prospective cohort studies. J Bone Miner Res 2011, 26(4):833-9.
• [47]Grey A, Bolland M: Web of industry, advocacy, and academia in the management of osteoporosis. BMJ 2015, 351:h3170.
• [48]Bolland MJ, Grey A, Reid IR: Calcium supplements and cardiovascular risk in the Women’s Health Initiative. Osteoporos Int 2013, 24(8):2371-2.
• [49]Paik JM, Curhan GC, Sun Q, Rexrode KM, Manson JE, Rimm EB, et al.: Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int 2014, 25(8):2047-56.
• [50]Kalkwarf HJ, Khoury JC, Lanphear BP: Milk intake during childhood and adolescence, adult bone density, and osteoporotic fractures in US women. Am J Clin Nutr 2003, 77(1):257-65.
• [51]Heaney RP: Dairy and bone health. J Am Coll Nutr 2009, 28(Suppl 1):82S-90S.
• [52]Rizzoli R: Dairy products, yogurts, and bone health. Am J Clin Nutr 2014, 99(5 Suppl):1256S-62S.
• [53]Fernandez-Barres S, Martin N, Canela T, Garcia-Barco M, Basora J, Arija V et al. Dietary intake in the dependent elderly: evaluation of the risk of nutritional deficit. J Hum Nutr Diet 2015. doi:10.1111/jhn.12310
• [54]Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, et al.: Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007, 18(10):1311-7.
• [55]Prince RL, Devine A, Dhaliwal SS, Dick IM: Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006, 166(8):869-75.
• [56]Hiligsmann M, Boonen A, Rabenda V, Reginster JY: The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2012, 12(2):159-66.
• [57]Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H: Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010, 121(2):469-77.
• [58]Murphy N, Norat T, Ferrari P, Jenab M, Bueno-de-Mesquita B, Skeie G, et al.: Consumption of dairy products and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS One 2013., 8(9) Article ID e72715
• [59]Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, et al.: Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014, 1:CD007470.